← Human Trials & Peer-Reviewed Studies
A Randomized Controlled Trial on the Effects of Leucine-Supplement Combined with Nutritional Counseling on Body Composition in Mix Cancer Older Men.
Plain-language guide to PMID 38257103 (2024): parallel-group randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 38257103
- Journal
- Nutrients
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Soares JDP et al. (4 authors)
- DOI
- 10.3390/nu16020210
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
The aim of this study was to evaluate the effect of leucine supplementation on body composition in outpatients with gastrointestinal tract cancer.
Why It Was Studied
In this sense, protein supplementation can be a strategy to help counteract the loss and/or maintenance of mass in these patients.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.
It was a randomized, blinded, controlled, parallel trial, performed in male patients with a cancer diagnosis of the gastrointestinal tract and appendix organs undergoing chemotherapy.
The intention-to-treat approach was performed to predict the missing values for all patients who provide any observation data.
How the Study Was Run
In design terms this was a randomized and parallel-group study.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Groups ran in parallel: each of the participants stayed in one arm throughout.
The researchers evaluated the body composition through bioelectrical impedance analysis, the cancer cachexia classification, and the diet intake before and after the intervention protocol.
What Was Measured
Topics PubMed links to this paper include Leucine, Cachexia, Neoplasms, Body Composition and Counseling.
The authors tagged it with the keywords cancer and nutritional counselling.
What This Means in Plain Language
The paper is a randomized and parallel-group study of Copper (Supplement).
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2024 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.